Browsing by Subject "Drug Delivery"
Now showing items 1-6 of 6
-
(2017-03-27)Department: Biomedical EngineeringOsteoarthritis (OA) is a disease characterized by degradation of joints with the development of painful inflammation in the surrounding tissues. Post-traumatic osteoarthritis (PTOA) is OA that develops following a traumatic ...
-
(2023-07-14)Department: Biomedical EngineeringGene editing unlocks the source code of life—DNA—for human engineering. This could enable treating myriad diseases, with huge academic and industrial efforts ongoing towards treatments for numerous cancers, neurodegenerative ...
-
(2022-03-27)Department: Biomedical EngineeringSmall interfering RNA (siRNA) has emerged as a potent regulator of gene expression, with the potential to treat a variety of previously “undruggable” diseases. However, its clinical translation has been limited due to short ...
-
(2009-12-02)Department: ChemistryConjugation of targeting, imaging and drug molecules to nanoparticles has been a developing area of interest over the last 10-15 years. Although great strides have been made, characterization and activity of functionalized ...
-
(2019-07-08)Department: Biomedical EngineeringWhile siRNA nanomedicine holds great potential for unlocking otherwise “undruggable” targets, it also faces significant delivery challenges to non-liver targets such as tumors. In particular, polymeric delivery vehicles ...
-
(2020-04-03)Department: Biomedical EngineeringOsteoarthritis (OA) is a debilitating and prevalent chronic disease, but there are no approved disease modifying OA drugs (DMOADs), only pharmaceuticals for pain management. OA progression, particularly for post-traumatic ...